Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the &apos;RTL&apos; (regional Tuscan lymphoma network)

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Am J Hematol

Tun AM, Patel RD, St-Pierre F, Ouchveridze E, Niu A, Thordardottir T, Obasi J, Rosenthal A, Pophali PA, Fenske TS, Karmali R, Ahmed S, Johnston PB

doi: 10.1002/ajh.27381

Lymphoma

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Br J Haematol

Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, El-Galaly TC, Villa D, Dickinson M, Seymour JF, Cheah CY

doi: 10.1111/bjh.19470

Lymphoma

Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study

Leuk Lymphoma

Hong D, Yin M, Li J, Deng Z, Ren Z, Zhou Y, Huang S, Yan X, Zhong W, Liu F, Yang C

doi: 10.1080/10428194.2024.2364830

Lymphoma

Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning

Leuk Lymphoma

Shumilov E, Levien L, Mazzeo P, Jung W, Leha A, Koch R, Hasenkamp J, Wulf G

doi: 10.1080/10428194.2024.2438805

Lymphoma

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

Blood Cancer J

Vaughn JL, Ramdhanny A, Munir M, Rimmalapudi S, Epperla N

doi: 10.1038/s41408-024-01194-5

Lymphoma

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

Blood Cancer J

Epperla N, Lucero M, Bailey T, Mirams L, Cheung J, Amet M, Milligan G, Chen L

doi: 10.1038/s41408-024-01195-4

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Haematologica

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC

doi: 10.3324/haematol.2024.285977

EHA 2024

Lymphoma

Oncology · Hematology

Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the 'RTL' (regional Tuscan lymphoma network)

Related content

Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Cardiovascular mortality among patients with diffuse large B-cell lymphoma: a population-based study

Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning

A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

STARGLO: Glofitamab combination therapy shows significant benefits in patients with relapsed/refractory diffuse large B-cell lymphoma